8-K: INmune Bio Presents MINDFul Trial Data at International Conference on Alzheimers and Parkinsons Diseases

INmune Bio presented a poster detailing patient demographics and biomarker status at enrollment in their MINDFul Phase II trial for early Alzheimers disease.

Summary

• INmune Bio Inc. presented a poster at the International Conference on Alzheimers and Parkinsons Diseases detailing the baseline characteristics of patients enrolled in the MINDFul Phase II clinical trial.
• The MINDFul trial is evaluating XPro1595 in patients with early Alzheimers disease and biomarkers of inflammation.
• The study is a 24-week, phase 2, randomized, double-blind, placebo-controlled trial.
• Patients with mild cognitive impairment (MCI) or mild AD (mAD) and biomarker evidence of amyloid pathology and immune dysfunction were enrolled.
• The enrollment goal was 201 patients randomized 2:1 to receive either XPro TM (1.0 mg/kg) or placebo by subcutaneous injection given once per week for 23 weeks.
• The primary outcome is the change from baseline in EMACC scores.
• Preliminary analyses of blinded data show enrollment of a well-characterized cohort of patients diagnosed with MCI or mAD with high precision.
• Top-line results from the MINDFul trial are expected in June 2025.
• Mean age of patients is 72.5 years.
• 69.2% of patients are APOE 4 carriers.
• 64.9% are positive for >1 enrichment biomarker of immune dysfunction.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as the company is progressing with a Phase II trial and presenting data at a major conference. However, the actual efficacy of the treatment is still unknown, pending the top-line results.

Positives

• The MINDFul trial is enriched for patients with biomarkers of immune system dysfunction and early-stage AD, deemed likely to benefit from treatment with XPro TM.
• The EMACC is an objective measure with the sensitivity necessary for detection of cognitive changes and treatment effects over the short-term in Early AD.
• Enrollment in the MINDFul trial was completed in November 2024.
• Preliminary analyses of blinded data show enrollment of a well-characterized cohort of patients diagnosed with MCI or mAD with high precision.

Risks

• The trial is still ongoing, and top-line results are not expected until June 2025, so the efficacy of XPro1595 is yet to be determined.
• The screen failure rate was driven by MMSE inclusion criteria, which may indicate challenges in patient selection.

Future Outlook

Top-line results from the MINDFul trial are expected in June 2025, which will provide insights into the efficacy of XPro1595.

Industry Context

This announcement is relevant to the broader pharmaceutical industry's efforts to develop effective treatments for Alzheimers disease, particularly those targeting inflammation and immune dysfunction. The MINDFul trial's focus on patients with specific biomarkers aligns with the trend towards personalized medicine in AD research.

Comparison to Industry Standards

• The MINDFul trial's design, including the use of the EMACC as a primary outcome measure, reflects current best practices in early AD clinical trials, as evidenced by presentations at conferences such as the International Conference on Clinical Trials in Alzheimer's Disease (CTAD).
• The trial's inclusion criteria, focusing on patients with amyloid pathology and immune dysfunction, aligns with the NIA-AA research framework for defining Alzheimers disease biologically.
• The baseline demographics and disease characteristics of the enrolled patients are consistent with published AD epidemiology and other Phase 2-3 clinical trials in AD, such as those referenced in the 2024 Alzheimer's disease facts and figures report.

Stakeholder Impact

• Positive results from the MINDFul trial could benefit patients with early Alzheimers disease and their families.
• Successful development of XPro1595 could create value for INmune Bio shareholders.
• The trial provides opportunities for researchers and clinicians to advance their understanding of Alzheimers disease.

Next Steps

• The company will continue to monitor patients in the MINDFul trial.
• The company will analyze the data collected during the trial.
• The company will report top-line results from the MINDFul trial in June 2025.

Key Dates

Keywords

Alzheimers Disease, INmune Bio, XPro1595, MINDFul Trial, Clinical Trial, Biomarkers, Inflammation, EMACC, Cognitive Impairment